GlucoTrack (GCTK)
NASDAQ:GCTK
Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.43 - $15.90
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$4.14M
Enterprise Value-$3.53M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding6,259,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit160.39
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IDE Submission To FDA (clinical Transition)Submitting an IDE marks a structural shift from preclinical to clinical development in the U.S., enabling generation of pivotal human data required for regulatory approvals. This advances the company down a defined regulatory pathway and materially increases the likelihood of future commercialization if trials succeed.
Peer-reviewed Preclinical And First-in-human DataRobust, peer-reviewed preclinical results and positive first-in-human data provide durable scientific validation of the implantable sensor's accuracy and safety. This evidence strengthens regulatory credibility, supports clinical trial design, and enhances prospects for clinician adoption and partner interest over the medium term.
Patents, Manufacturing And Commercialization PlanningA growing IP portfolio plus defined manufacturing and reimbursement strategies and experienced management create structural advantages for market entry and scale. Patents protect core technology, dual sourcing reduces supply risk, and seasoned leadership improves execution odds during clinical and commercial stages.
Bears Say
No Revenue; Persistent Cash BurnSustained negative operating and free cash flow with essentially no revenue creates an ongoing funding imperative. Over months, this elevates dilution and financing risk, constrains R&D and commercial investment flexibility, and heightens the chance the company must secure dilutive capital before revenue emerges.
Negative Stockholders' EquityNegative equity indicates cumulative losses have eroded book value, reducing financial flexibility and increasing vulnerability to creditor or listing-rule actions. It can hamper the company's ability to raise non-dilutive capital, heighten financing costs, and weaken partner confidence over the medium term.
Material Nasdaq Delisting RiskMultiple deficiency notices and potential delisting introduce structural uncertainty for liquidity, institutional access, and raising capital. If listing status is lost or threatened, the company may face higher fundraising costs, reduced investor access, and operational distraction from core development activities.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.43 and its highest was $15.90 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $4.14M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Aug 13, 2026 which is in 69 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on May 14, 2026. The company reported -$2.646 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.646.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 6,259,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$2.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.84%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Technical Analysis
Ownership Overview
0.18% Insiders
0.18% Mutual Funds
0.80% Other Institutional Investors
98.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---